Researchers identify possible new target in fight against lung cancer

September 12, 2017
Researchers discovered microRNAs that suppress cancer cell growth. Credit: A.K. Mehta et al., Science Signaling (2017)

Researchers at Boston University School of Medicine (BUSM) have identified a molecule called miR-124 in non-small cell lung cancer cells that plays a regulatory role in the cancer cells' fate—determining whether or not the specific subtype of cancer cell will undergo programmed cell death.

The findings, which appear in Science Signaling, may offer a new target in the fight against non-small cell lung cancer.

According to the researchers, the molecule miR-124 causes programmed in a specific subtype of that has undergone a switch known as epithelial to mesenchymal transformation. These mesenchymal-like cells, which have mutations in a cancer gene called KRAS, are typically resistant to the death-inducing effects of chemotherapeutic agents.

By analyzing human lung cancer derived cell lines, the researchers were able to determine the unique profiles of two subtypes of lung cancer cells. Upon comparing biochemical profiles they were able to identify the miR-124 molecule as the major player in the signaling cascade that determines whether or not the specific cell type will live or die.

"Lung cancers display widespread genetic, molecular and phenotypic variability and heterogeneity. It is critical to understand the implications of this heterogeneity to identify effective targeted therapeutic regimens and clinical diagnostics," explained corresponding author Anurag Singh, PhD, assistant professor of pharmacology and medicine at BUSM. "Understanding the mechanisms that are associated with phenotypic heterogeneity in lung cancer cells—specifically differences between epithelial and mesenchymal-like cells—allows these differences to be exploited to develop more selective therapeutic agents."

Scientists discovered microRNAs that cause growth defects in cancer cells (indicated by red arrows in right panels). Credit: A.K. Mehta et al., Science Signaling (2017)

The researchers hope their discovery leads to pre-clinical and early phase clinical trials to treat non-small cell lung cancer , however additional work must be done to explore this possible therapeutic target.

The American Cancer Society's estimates for lung cancer in the United States for 2017 are about 222,500 new cases of lung cancer and about 155,870 deaths from lung . About 80 to 85 percent of lung cancers are non-small cell .

Explore further: Unique lipid profile could help diagnose and treat lung cancer

More information: "Regulation of autophagy, NF-κB signaling, and cell viability by miR-124 in KRAS mutant mesenchymal-like NSCLC cells," Science Signaling (2017). stke.sciencemag.org/lookup/doi … 26/scisignal.aam6291

Related Stories

Unique lipid profile could help diagnose and treat lung cancer

September 8, 2017
The lipid contents of a fluid that surrounds the lungs in some diseases contains specific fats that could be used as a biomarker to distinguish people with and without lung cancer. It can also identify a subtype of the cancer ...

Mutations unveiled that predispose lung cancers to refractory histologic transformation

June 7, 2017
Cancer pedigree analysis reveals the mutations in RB1 and TP53 genes play a key role in treatment-resistant, cancer cell-type transformation during EGFR inhibitor therapy for lung cancers.

New study proves one lung cancer subtype can switch to another

April 14, 2017
A new study co-authored by a researcher starting her laboratory at the University of Kentucky Markey Cancer Center shows that in certain genetic situations, one non-small cell lung cancer subtype can change into another subtype.

Before a cure, a crusade to stop lung cancer from spreading

November 11, 2016
The American Cancer Society has reported that lung cancer, which kills more Americans than any other type of cancer, is expected result in an estimated 158,080 deaths in 2016.

Researchers discover molecular approach to promote cancer cell death

May 21, 2015
Lung cancer researchers at Winship Cancer Institute of Emory University have discovered a novel strategy to exploit apoptosis, a form of programmed cell death, for the treatment of lung cancer. The protein Bcl-2 is a known ...

Researchers uncover powerful new class of weapons in the war on cancer

October 22, 2014
An interdisciplinary team of researchers from the University of Texas Medical Branch, and Winship Cancer Institute of Emory University have identified small molecules that can represent a new class of anticancer drugs with ...

Recommended for you

Alternative splicing, an important mechanism for cancer

September 22, 2017
Cancer, which is one of the leading causes of death worldwide, arises from the disruption of essential mechanisms of the normal cell life cycle, such as replication control, DNA repair and cell death. Thanks to the advances ...

'Labyrinth' chip could help monitor aggressive cancer stem cells

September 21, 2017
Inspired by the Labyrinth of Greek mythology, a new chip etched with fluid channels sends blood samples through a hydrodynamic maze to separate out rare circulating cancer cells into a relatively clean stream for analysis. ...

Whole food diet may help prevent colon cancer, other chronic conditions

September 21, 2017
A diet that includes plenty of colorful vegetables and fruits may contain compounds that can stop colon cancer and inflammatory bowel diseases in pigs, according to an international team of researchers. Understanding how ...

Drug combination may improve impact of immunotherapy in head and neck cancer

September 21, 2017
Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego School of Medicine researchers ...

New kinase detection method helps identify targets for developing cancer drugs

September 21, 2017
Purdue University researchers have developed a high-throughput method for matching kinases to the proteins they phosphorylate, speeding the ability to identify multiple potential cancer drug targets.

Brain cancer growth halted by absence of protein, study finds

September 20, 2017
The growth of certain aggressive brain tumors can be halted by cutting off their access to a signaling molecule produced by the brain's nerve cells, according to a new study by researchers at the Stanford University School ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.